Japan-based pharmaceutical group Takeda’s corporate venturing unit has helped Juventas Therapeutics, a US-based regenerative medicine company, raise $22.2m.
Takeda Ventures was joined in the series B round by venture firms Triathlon Medical Venture Partners and New Science Ventures, which co-led the round. The Global Cardiovascular Innovation Center and venture firms
Fletcher Spaght Ventures, Reservoir Venture Partners and Early Stage Partners, Venture Investors, Tri-State Growth Fund, Glengary and angel investors also participated.
Last year, Juventas Therapeutics spun-off from SironRX Therapeutics to focus on dermal and bone related applications for its technology, JVS-100.
In 2011, SironRX raised $3.4m in its Series A led by angel firm North Coast Angel Fund and received $1m in grant funding through the Ohio Third Frontier program.
Other backers include X Gen, JumpStart, and Blue Chip Venture Co. The company also received non-dilutive grants from Ohio Third Frontier-funded Cleveland Clinic Ohio BioValidation Fund, Global Cardiovascular Innovation Center and Center for Stem Cell & Regenerative Medicine.